Skip to main content

TNF inhibitor

      Most patients with early, active axial spondyloarthritis (axSpA) who quickly received a tumor necrosis factor (TNF) inhibitor experienced remission, and it didn't matter whether or not they had intestinal inflammation at baseline, a small single-arm study found.
      Women with antiphospholipid syndrome and lupus anti-coagulant are at high risk of developing adverse pregnancy outcomes (APO). Usual care includes low molecular weight heparin (LMWH) and low dose aspirin (LDA). Despite these therapies, APO have been reported up to 40%. An important question is whether add-on immunosuppressive therapy could improve APO.
      Combination treatments in Psoriatic Arthritis

      Psoriatic arthritis (PsA) is a complex inflammatory arthritis with multi

      Dr. John Cush RheumNow

      2 weeks 6 days ago
      Combination treatments in Psoriatic Arthritis Psoriatic arthritis (PsA) is a complex inflammatory arthritis with multiple domains and associated comorbidities. Despite the advances in the treatment of PsA with biologic (bDMARD) and targeted synthetic (tsDMARD), less than half https://t.co/rSkoE236hR
      Why is RA Difficult to Treat?
      At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; it’s about understanding the unique constellation of domains, comorbidities, and patient factors that shape each clinical decision.
      Impact of TNFi on efficacy of Vunakizumab in AS.
      -Post hoc analysis of Vunakizumab
      (humanized monoclonal IgG1/k antibod

      Adela Castro AdelaCastro222

      3 weeks 1 day ago
      Impact of TNFi on efficacy of Vunakizumab in AS. -Post hoc analysis of Vunakizumab (humanized monoclonal IgG1/k antibody targeting IL-17A) trial on AS pts. -440 total pts, 163 had prior TNFi exposure - At week 16, no significant differences in ASAS20 b/w TNFi exposed pts https://t.co/O9PFOuLa5l
      In BIODOPT study (RA, PsA, axSpA), disease activity-guided tapering of biologics (incl. biosimilars) maintained QALY (Δ

      Antoni Chan MD (Prof) synovialjoints

      3 weeks 1 day ago
      In BIODOPT study (RA, PsA, axSpA), disease activity-guided tapering of biologics (incl. biosimilars) maintained QALY (Δ0.008, NS) while lowering biologic costs (Δ€–1,979 [95%CI –3,798;–161]) & total hospital costs (Δ€–1,936 [95%CI –3,753;–119]) over 18mo. Supports https://t.co/CJUpfU2oRA
      Biologic switching in PsA:
      -Retrospective study on 3,851 PsA pts initiating bDMARDs, 1,848 (48%) switched therapy at lea

      Adela Castro AdelaCastro222

      3 weeks 1 day ago
      Biologic switching in PsA: -Retrospective study on 3,851 PsA pts initiating bDMARDs, 1,848 (48%) switched therapy at least once. -TNFis were the initial therapy. -IL17i were the first switch in both single-switch and multi-switch scenarios. -Subsequent switches: back to TNFi https://t.co/tJDJvPeu9T
      Data from COAST-V study (post hoc)

      🔹️Ixekizumab in #axSpA
      🔹️Efficacy stratified by CRP level
      🔹️Better tr

      Nelly ZIADE 🍀 Nellziade

      3 weeks 1 day ago
      Data from COAST-V study (post hoc) 🔹️Ixekizumab in #axSpA 🔹️Efficacy stratified by CRP level 🔹️Better treatment response in the elevated compared to the normal CRP group OP0699 #EULAR2025 @RheumNow https://t.co/1mVoly3Gws
      In RCT of RA pts in remission/low disease activity, spacing ozoralizumab (next gen TNFi) or reducing MTX led to more fla

      Mrinalini Dey DrMiniDey

      3 weeks 1 day ago
      In RCT of RA pts in remission/low disease activity, spacing ozoralizumab (next gen TNFi) or reducing MTX led to more flares vs continued tx; but most pts in remission at baseline maintained LDAS. Remission matters for subsequent Tx reduction. @RheumNow #EULAR2025 #LB0006
      APEX study Ph3 RCT Guselkumab
      In BioNaive active PsA w/ erosions>=2

      wk 24

      ACR20 GUS Q4W 67% Q8W 68% vs PBO 47%
      Less

      Aurelie Najm AurelieRheumo

      3 weeks 1 day ago
      APEX study Ph3 RCT Guselkumab In BioNaive active PsA w/ erosions>=2 wk 24 ACR20 GUS Q4W 67% Q8W 68% vs PBO 47% Less Rx progression in both Q4W & Q8W vs. PBO #EULAR2025 @RheumNow LB0010 https://t.co/OVDWWECtOZ
      APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA
      ✅ ACR20: 67–68% vs 47% (PBO)
      ✅ ↓radio

      Mrinalini Dey DrMiniDey

      3 weeks 1 day ago
      APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA ✅ ACR20: 67–68% vs 47% (PBO) ✅ ↓radiographic progression (vdH-S: 0.55/0.54 vs 1.35) No new safety signals identified. @RheumNow #EULAR2025 #LB0010 https://t.co/LLN1TXvOC3
      Management and prognosis of RP by @Lupusreference
      1. Pts with mild disease respond to GCs
      2. NSAIDs/colchicine good alt

      Adela Castro AdelaCastro222

      3 weeks 1 day ago
      Management and prognosis of RP by @Lupusreference 1. Pts with mild disease respond to GCs 2. NSAIDs/colchicine good alternatives 3. Most common biologics used: TNFi and IL6i 4. Consider CYP in life threatening dz/ICU pts 5. Dynamic CT assess tracheal collapse. 6. PET-CT can ≠ https://t.co/PNUecMZvkT
      ×